Literature DB >> 17932492

Proteins, drug targets and the mechanisms they control: the simple truth about complex networks.

Robyn P Araujo1, Lance A Liotta, Emanuel F Petricoin.   

Abstract

Realizing the promise of molecularly targeted inhibitors for cancer therapy will require a new level of knowledge about how a drug target is wired into the control circuitry of a complex cellular network. Here we review general homeostatic principles of cellular networks that enable the cell to be resilient in the face of molecular perturbations, while at the same time being sensitive to subtle input signals. Insights into such mechanisms may facilitate the development of combination therapies that take advantage of the cellular control circuitry, with the aim of achieving higher efficacy at a lower drug dosage and with a reduced probability of drug-resistance development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932492     DOI: 10.1038/nrd2381

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  67 in total

1.  Drug discovery: engineering drug combinations.

Authors:  Scott J Dixon; Brent R Stockwell
Journal:  Nat Chem Biol       Date:  2010-05       Impact factor: 15.040

2.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.

Authors:  Sergio Iadevaia; Yiling Lu; Fabiana C Morales; Gordon B Mills; Prahlad T Ram
Journal:  Cancer Res       Date:  2010-07-19       Impact factor: 12.701

3.  Optimal homeostasis necessitates bistable control.

Authors:  Guanyu Wang
Journal:  J R Soc Interface       Date:  2012-04-25       Impact factor: 4.118

4.  A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Authors:  Virginia Espina; Kirsten H Edmiston; Michael Heiby; Mariaelena Pierobon; Manuela Sciro; Barbara Merritt; Stacey Banks; Jianghong Deng; Amy J VanMeter; David H Geho; Lucia Pastore; Joel Sennesh; Emanuel F Petricoin; Lance A Liotta
Journal:  Mol Cell Proteomics       Date:  2008-07-30       Impact factor: 5.911

Review 5.  Models of signalling networks - what cell biologists can gain from them and give to them.

Authors:  Kevin A Janes; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2013-05-01       Impact factor: 5.285

6.  The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs?

Authors:  Gerald M Maggiora
Journal:  J Comput Aided Mol Des       Date:  2011-06-23       Impact factor: 3.686

Review 7.  Dissecting cancer through mathematics: from the cell to the animal model.

Authors:  Helen M Byrne
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

8.  Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Authors:  Tilman Brummer; Mark Larance; Maria Teresa Herrera Abreu; Ruth J Lyons; Paul Timpson; Christoph H Emmerich; Emmy D G Fleuren; Gillian M Lehrbach; Daniel Schramek; Michael Guilhaus; David E James; Roger J Daly
Journal:  EMBO J       Date:  2008-09-03       Impact factor: 11.598

9.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

10.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Authors:  Veronique M Neumeister; Valsamo Anagnostou; Summar Siddiqui; Allison Michal England; Elizabeth R Zarrella; Maria Vassilakopoulou; Fabio Parisi; Yuval Kluger; David G Hicks; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2012-10-22       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.